Drug Trial Radar · NCT02954874
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,195
Actual
Start
Jan 18, 2017
Primary completion
Aug 3, 2026
Study completion Aug 27, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions
- Breast Carcinoma In Situ
- Invasive Breast Carcinoma
- Stage I Breast Cancer AJCC v7
- Stage II Breast Cancer AJCC v6 and v7
- Stage III Breast Cancer AJCC v7
- Triple-Negative Breast Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood samples
Laboratory Biomarker AnalysisOther
Correlative studies
Patient ObservationOther
Undergo standard monitoring
PembrolizumabBiological
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Undergo radiation therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease-free survival (IDFS)Time frame: From date of randomization to date of first invasive recurrence, second invasive primary cancer (breast or not), or death due to any cause, assessed up to 10 years
- Severity of fatigueTime frame: 55 weeks after randomization
- Physical functionTime frame: 55 weeks after randomization
Locations
919 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Southern Cancer Center PC-Daphne
Daphne, Alabama
Southern Cancer Center PC-Mobile
Mobile, Alabama
Southern Cancer Center PC-Providence
Mobile, Alabama
Southern Cancer Center PC-Springhill
Mobile, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Banner MD Anderson Cancer Center
Gilbert, Arizona
CTCA at Western Regional Medical Center
Goodyear, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Highlands Oncology Group - Rogers
Rogers, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Mills-Peninsula Medical Center
Burlingame, California
Community Cancer Institute
Clovis, California
City of Hope Corona
Corona, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
City of Hope Comprehensive Cancer Center
Duarte, California
Epic Care-Dublin
Dublin, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Washington Health
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Saint Jude Medical Center
Fullerton, California
Showing 40 of 919 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.